Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Part of paid clinical trials in Wilmington, North Carolina.

Sponsor
Deciphera Pharmaceuticals, LLC
Study ID
NCT07075471
Status
Recruiting
Apply to this trial

Conditions

  • Tenosynovial Giant Cell Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Key Dates

Start date
Sep 3, 2025
Status verified
Nov 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Duration of Vimseltinib Treatment [ Time Frame: Baseline up to 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Synexus Clinical Research, US INCWilmingtonNorth Carolina28401
888-581-9246

Find similar trials in Wilmington, NC

By research site
Synexus Clinical Research, US INC· Wilmington, NC

Related Studies